KYNTRA BIO, INC. (KYNB)
About KYNTRA BIO, INC.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $6.4M
- Net income
- $183.5M
- Total assets
- $119.6M
- Market cap
- $27.2M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $27.2M
- Shares outstanding
- 3.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 14, 2014
Kyntra BIO, Inc. (KYNB) Stock Price
- Profitable — net income of $183.5M in FY2025.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review KYNTRA BIO, INC..
Write a review
News about KYNTRA BIO, INC.
News & sentiment via Polygon.io
Kyntra BIO, Inc.: frequently asked questions
Is Kyntra BIO, Inc. an American company?
Kyntra BIO, Inc. is a US-based company headquartered in San Francisco, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Kyntra BIO, Inc. headquartered?
Kyntra BIO, Inc. is headquartered in San Francisco, California, United States.
Is Kyntra BIO, Inc. publicly traded?
Yes — Kyntra BIO, Inc. is a publicly traded company. Its stock trades under the ticker symbol KYNB on the NASDAQ.
What does Kyntra BIO, Inc. do?
Kyntra BIO, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
